Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Brooks

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Cancer Research|November 29, 2017
Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic CancerJennifer Brooks, Bettina Fleischmann-Mundt, Norman Woller, et al.
Gynecologic Oncology|January 22, 2022
Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutationYue Yin Xia, Jacek Gronwald, Beth Karlan, et al.
Journal of Medicinal Chemistry|April 16, 2004
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymeraseAnne B Eldrup, Charles R Allerson, C Frank Bennett, et al.
Gastroenterology|May 24, 2016
Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer CellsEngin Gürlevik, Bettina Fleischmann-Mundt, Jennifer Brooks, et al.
The Journal of Allergy and Clinical Immunology|July 6, 2024
Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonistsJoshua Wollam, Michelle Solomon, Christiane Villescaz, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessmentsLian-Sheng Li, Yuefen Zhou, Douglas E Murphy, et al.
Communications Medicine|April 21, 2026
Perspectives from a multi-stakeholder workshop for implementing a risk-stratified breast cancer screening program in CanadaNareh Safieh-Garabedian, Antonis C Antoniou, Jennifer Brooks, et al.
Journal of Medicinal Chemistry|October 1, 2004
Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replicationAnne B Eldrup, Marija Prhavc, Jennifer Brooks, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymeraseFrank Ruebsam, Douglas E Murphy, Chinh V Tran, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Cancer Research|November 29, 2017
Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic CancerJennifer Brooks, Bettina Fleischmann-Mundt, Norman Woller, et al.
Gynecologic Oncology|January 22, 2022
Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutationYue Yin Xia, Jacek Gronwald, Beth Karlan, et al.
Journal of Medicinal Chemistry|April 16, 2004
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymeraseAnne B Eldrup, Charles R Allerson, C Frank Bennett, et al.
Gastroenterology|May 24, 2016
Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer CellsEngin Gürlevik, Bettina Fleischmann-Mundt, Jennifer Brooks, et al.
The Journal of Allergy and Clinical Immunology|July 6, 2024
Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonistsJoshua Wollam, Michelle Solomon, Christiane Villescaz, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2008
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessmentsLian-Sheng Li, Yuefen Zhou, Douglas E Murphy, et al.
Communications Medicine|April 21, 2026
Perspectives from a multi-stakeholder workshop for implementing a risk-stratified breast cancer screening program in CanadaNareh Safieh-Garabedian, Antonis C Antoniou, Jennifer Brooks, et al.
Journal of Medicinal Chemistry|October 1, 2004
Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replicationAnne B Eldrup, Marija Prhavc, Jennifer Brooks, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2009
Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymeraseFrank Ruebsam, Douglas E Murphy, Chinh V Tran, et al.
Pageof 4